Peter Mueller, PhD.
Dr. Mueller joined Vertex in July 2003.
As Executive Vice President Global Research and Development & Chief Scientific Officer, he provides strategic oversight for Vertex's worldwide drug discovery research programs, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations as well as Clinical and Non-Clinical Development, Regulatory, Patient Safety and Medical Affairs.
Key areas of Vertex'
R&D are Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases which led in 2011 to the successful approval and launch of INCIVEK (HepC), a NDA/MAA submission for KALYDECO (CF) with the first approval in the US in January 2012 and several proof of clinical concept candidates in various disease areas.
Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997.
also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis.
time with Boehringer Ingelheim
, Dr. Mueller
oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry.
completed fellowships in Quantum Pharmacology at Oxford University
and in Biophysics at Rochester University